Page title
Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
TIP 63: Medications for Opioid Use Disorder - Executive Summary
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
TIP 63: Medications for Opioid Use Disorder - Full Document
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
The Facts about Buprenorphine for Treatment of Opioid Addiction (Korean Version)
Published: December 2015
This Korean-language brochure gives patients information on buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
Tips for Disaster Responders: Identifying Substance Misuse In The Responder Community (Spanish Version)
Published: September 2014
Ayuda a los socorristas a identificar cuáles son las señales de advertencia del uso indebido del alcohol, de medicamentos recetados y de otras sustancias. Repasa los indicadores físicos, emocionales, sociales, conductuales y mentales de un posible abuso de sustancias y ayuda a determinar cuándo deben buscar ayuda.
TIP 47: Substance Abuse: Clinical Issues in Intensive Outpatient Treatment
Published: December 2013
This manual helps clinicians design and implement intensive outpatient treatment programs for people living with substance use disorder conditions. It discusses cultural competence and approaches, use of 12-step programs, cognitive behavioral therapy, and therapeutic communities.